Ya-rong Zhang

Beijing, 100083, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Intermedin Inhibits DNA Damage-Promoted Senescent Phenotype Transition of Vascular Smooth Muscle Cells in Aorta by Activating NAMPT/PARP1 in Mice.

Intermedin Inhibits DNA Damage-Promoted Senescent Phenotype Transition of Vascular Smooth Muscle Cells in Aorta by Activating NAMPT/PARP1 in Mice.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: June 25, 2025

Intermedin1-53 improves aging-associated cardiac remodeling and dysfunction via mitochondrial SIRT3-mediated SOD2 deacetylation.

Intermedin1-53 improves aging-associated cardiac remodeling and dysfunction via mitochondrial SIRT3-mediated SOD2 deacetylation.

Journal: Journal of molecular and cellular cardiology

Published: December 26, 2024

Intermedin Alleviates Diabetic Cardiomyopathy by Up-Regulating CPT-1β through Activation of the Phosphatidyl Inositol 3 Kinase/Protein Kinase B Signaling Pathway.

Intermedin Alleviates Diabetic Cardiomyopathy by Up-Regulating CPT-1β through Activation of the Phosphatidyl Inositol 3 Kinase/Protein Kinase B Signaling Pathway.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: June 28, 2024

Intermedin alleviates diabetic vascular calcification by inhibiting GLUT1 through activation of the cAMP/PKA signaling pathway.

Intermedin alleviates diabetic vascular calcification by inhibiting GLUT1 through activation of the cAMP/PKA signaling pathway.

Journal: Atherosclerosis

Published: September 02, 2022

Intermedin Alleviates Vascular Calcification in CKD through Sirtuin 3-Mediated Inhibition of Mitochondrial Oxidative Stress.

Intermedin Alleviates Vascular Calcification in CKD through Sirtuin 3-Mediated Inhibition of Mitochondrial Oxidative Stress.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: August 29, 2022

Plasma Level of Elabela in Patients with Coronary Heart Disease and Its Correlation with the Disease Classification.

Plasma Level of Elabela in Patients with Coronary Heart Disease and Its Correlation with the Disease Classification.

Journal: International heart journal

Published: July 19, 2021

Intermedin1-53 attenuates atherosclerotic plaque vulnerability by inhibiting CHOP-mediated apoptosis and inflammasome in macrophages.

Intermedin1-53 attenuates atherosclerotic plaque vulnerability by inhibiting CHOP-mediated apoptosis and inflammasome in macrophages.

Journal: Cell death & disease

Published: January 26, 2021

STAT3 Promotes Schistosome-Induced Liver Injury by Inflammation, Oxidative Stress, Proliferation, and Apoptosis Signal Pathway.

STAT3 Promotes Schistosome-Induced Liver Injury by Inflammation, Oxidative Stress, Proliferation, and Apoptosis Signal Pathway.

Journal: Infection and immunity

Published: May 26, 2020

Inhibition of Notch1-mediated inflammation by intermedin protects against abdominal aortic aneurysm via PI3K/Akt signaling pathway.

Inhibition of Notch1-mediated inflammation by intermedin protects against abdominal aortic aneurysm via PI3K/Akt signaling pathway.

Journal: Aging

Published: April 03, 2020

Intermedin alleviates pathological cardiac remodeling by upregulating klotho.

Intermedin alleviates pathological cardiac remodeling by upregulating klotho.

Journal: Pharmacological research

Published: November 28, 2019

Taurine Alleviates Schistosoma-Induced Liver Injury by Inhibiting the TXNIP/NLRP3 Inflammasome Signal Pathway and Pyroptosis.

Taurine Alleviates Schistosoma-Induced Liver Injury by Inhibiting the TXNIP/NLRP3 Inflammasome Signal Pathway and Pyroptosis.

Journal: Infection and immunity

Published: September 17, 2019

Intermedin1-53 attenuates aging-associated vascular calcification in rats by upregulating sirtuin 1.

Intermedin1-53 attenuates aging-associated vascular calcification in rats by upregulating sirtuin 1.

Journal: Aging

Published: September 06, 2019

Showing 1-12 of 13

Last Updated: 09/26/2026